Display Settings:

Items per page
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 6

1.
Figure 1

Figure 1. From: A Safety Assessment of Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis.

Typical presentation of atopic dermatitis.

Mark Lebwohl, et al. MedGenMed. 2006;8(4):8-8.
2.
Figure 4

Figure 4. From: A Safety Assessment of Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis.

No effect of treatment with tacrolimus 0.03% or hydrocortisone ointment on the immediate response or on T-cell-dependent antibody response after vaccination in children (2–11 years of age) with moderate-to-severe AD. Reprinted with permission from Arch Dis Child.[49] Copyright 2006, British Medical Association.

Mark Lebwohl, et al. MedGenMed. 2006;8(4):8-8.
3.
Figure 3

Figure 3. From: A Safety Assessment of Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis.

Percentage of patients in a 6-month study in adults (N = 192) and a 1-year study in children aged 2–17 years (N = 713) who were treated with pimecrolimus cream 1% who had no flares throughout the entire study period compared with patients in the control group who were treated with vehicle cream. Adapted with permission from Dermatology and Pediatrics.[27,28] Copyright 2002, American Academy of Pediatrics. Copyright 2005, Karger.

Mark Lebwohl, et al. MedGenMed. 2006;8(4):8-8.
4.
Figure 5

Figure 5. From: A Safety Assessment of Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis.

Mean area under the time-concentration curves of tacrolimus and pimecrolimus in animal and human studies. International Conference on Harmonisation (ICH) Guidelines: Maximum recommended human dose (MRHD) (highest mean exposure) of 25 times or greater represents an adequate safety margin. In murine toxicology studies, no malignancies were observed with exposure to tacrolimus ointment 0.03% at 10 times the MRHD; at 26 times the MRHD, lymphoma was seen with tacrolimus ointment 0.1%.[12,37,57] NOAEL = no observed adverse-effect level; LOAEL = lowest observed adverse-effect level.

Mark Lebwohl, et al. MedGenMed. 2006;8(4):8-8.
5.
Figure 6

Figure 6. From: A Safety Assessment of Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis.

Mean area under the time-concentration curves (AUCs) of tacrolimus and pimecrolimus in animal and human studies. International Conference on Harmonisation (ICH) Guidelines: Maximum recommended human dose (MRHD) (highest mean exposure) of 25 times or greater represents an adequate safety margin. No malignancies were observed in mice that were treated for 2 years with exposure to pimecrolimus at 45 times the MRHD in adult patients; at 77 times the MRHD, lymphoma was seen.[12,37,57] NOAEL = no observed adverse-effect level; LOAEL = lowest observed adverse-effect level.

Mark Lebwohl, et al. MedGenMed. 2006;8(4):8-8.
6.
Figure 2

Figure 2. From: A Safety Assessment of Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis.

Percentage of patients achieving success of therapy (defined as “clear” or “almost clear” on the basis of the Investigator's Global Assessment) in 2 independent, randomized, double-blind studies of tacrolimus ointment 0.03% vs vehicle in the treatment of pediatric (2–15 years of age) and adult (≥ 16 years of age) patients with mild-to-moderate atopic dermatitis covering 2% to 30% of total body surface area (end of study; *P = .003, P < .001). Reprinted with permission from J Am Acad Dermatol.[22] Copyright 2005, Mosby.

Mark Lebwohl, et al. MedGenMed. 2006;8(4):8-8.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk